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Generates DNA substitutions and 
Deletions in Myeloma Cells
Hiroyuki Yamazaki1, Kotaro shirakawa1, tadahiko Matsumoto1, shigeki Hirabayashi  1,2,  
Yasuhiro Murakawa2,3, Masayuki Kobayashi  1, Anamaria Daniela sarca  1, 
Yasuhiro Kazuma1, Hiroyuki Matsui1, Wataru Maruyama1, Hirofumi Fukuda1, 
Ryutaro shirakawa4, Keisuke shindo1, Masaki Ri5, shinsuke Iida5 & Akifumi takaori-Kondo  1
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (ApoBeC) DNA cytosine deaminases 
have emerged as potential genomic mutators in various cancers. Multiple myeloma accumulates 
ApoBeC signature mutations as it progresses; however, the mechanisms underlying ApoBeC signature 
acquisition and its consequences remain elusive. In this study, we examined the significance and clinical 
impact of APOBEC3B (A3B) activity in multiple myeloma. Among APOBECs, only highly expressed 
A3B was associated with poor prognosis in myeloma patients, independent of other known poor 
prognostic factors. Quantitative PCR revealed that CD138-positive primary myeloma cells and myeloma 
cell lines exhibited remarkably high A3B expression levels. Interestingly, lentiviral A3B knockdown 
prevented the generation of deletion and loss-of-function mutations in exogenous DNA, whereas in 
control cells, these mutations accumulated with time. A3B knockdown also decreased the basal levels 
of γ-H2AX foci, suggesting that A3B promotes constitutive DNA double-strand breaks in myeloma 
cells. Importantly, among control shRNA-transduced cells, we observed the generation of clones that 
harboured diverse mutations in exogenous genes and several endogenous genes frequently mutated 
in myeloma, including TP53. Taken together, the results suggest that A3B constitutively mutates the 
tumour genome beyond the protection of the DNA repair system, which may lead to clonal evolution 
and genomic instability in myeloma.
Multiple myeloma (MM) is a plasma cell malignancy that harbours a wide variety of genetic alterations, including 
base substitutions, translocations, copy number variations and aneuploidy1,2. MM develops from monoclonal 
gammopathy of undetermined significance (MGUS) by accumulating genomic DNA mutations during phys-
iological B cell maturation3. According to the classic karyotypic classification system, MM/MGUS is divided 
into two subtypes: hyperdiploid, which is characterized by multiple trisomies of odd-numbered chromosomes 
and a lack of recurrent immunoglobulin gene translocations, and non-hyperdiploid, which is characterized by 
chromosome translocations t(4;14), t(14;16), t(14;20), t(6;14) and t(11;14)4. Among these karyotypic changes, 
ectopic expression of cyclin D is relatively often detected, either directly through its juxtaposition to an immuno-
globulin enhancer and copy number amplification or indirectly through unidentified mechanisms4. Most of the 
translocations are caused by errors in immunoglobulin heavy chain (IgH) class switch recombination and V(D)
J recombination3, while the rest are caused by errors in somatic hypermutation during plasma cell development 
in germinal centers5. Thus, these translocations are referred to as primary translocations and are considered the 
primary steps of oncogenesis in normal plasma cells6. Based on its expression profiles, MM is divided into seven 
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signature groups similar to its cytogenetic classifications: CD-1 and CD-2 (CCND1/CCND3), HY (hyperdiploid), 
LB (low bone disease), MS (MMSET), MF (c-MAF/MAF-B) and PR (proliferation). These signature groups are 
correlated with clinical prognosis: MS, MF and PR are correlated with high risk and CD-1, CD-2, HY, and LB are 
correlated with low risk7. DNA hypomethylation, deletion of chromosome 13, MYC dysregulation, and driver 
mutations of RAS and BRAF are considered signs of malignant progression8. Particular translocations of the 
MUM1/IRF4 (6p25), MAFB (20q11), IRTA2 (1q21) and MYC (8q24) loci, which rarely involve immunoglobulin 
genes, are correlated with poor clinical outcomes6. Furthermore, during MM progression and relapse, additional 
genetic abnormalities such as dysregulation of the NF-κB pathway, loss of chromosome 17p and/or abnormalities 
of TP53 develop and contribute to achieving independence from the bone marrow microenvironment4,8.
As with many other cancers, the presence of different subclones within MM tumours that are characterized by 
distinct genetic mutations independently contributes to MM progression9. High levels of intra-tumoural clonal 
heterogeneity and alterations in clonal dominance under therapeutic selective pressure have been described in 
patients with high-risk MM10. Hence, the molecular events underlying myeloma development and progression 
do no proceed in a linear fashion but rather through a Darwinian branching model9–11. Nevertheless, the causes 
of these events are largely unknown. Although activation-induced cytidine deaminase (AID) is considered to be 
responsible for early oncogenic processes, i.e., initiation of MM/MGUS, myeloma cells usually do not express 
AID12 except when interacting with dendritic cells13. Strikingly, whole-genome sequencing has revealed that 
MM contains apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) signature muta-
tions11,14–16. Accumulation of APOBEC signature mutations increases significantly during tumour recurrence 
and extramedullary extension11 and is associated with poor prognosis16,17. Moreover, kataegis, which is defined 
by hypermutation in localized genomic regions and is supposedly generated by APOBECs18, has been found at 
MYC/IGK or IGL translocation breakpoints16, suggesting the co-occurrence of chromosomal translocations and 
APOBEC-associated mutations.
APOBEC3B (A3B) is an APOBEC cytidine deaminase that plays critical roles in immunity and is now high-
lighted as an intrinsic mutagen of genomic DNA that induces C-to-T and C-to-G substitutions, especially in 
breast cancer19–22. Among the seven APOBEC3 enzymes (APOBEC3A/B/C/DE/F/G/H; A3A–A3H), A3B is 
the only family member that is predominantly located in the nucleus throughout the cell cycle23. We previously 
reported that A3B induces C-to-T transitions in genomic DNA in human cell culture models24; therefore, we 
hypothesized that A3B might also induce DNA mutations in MM. In this study, we investigated the mutagenic 
activity of A3B in myeloma cells, and we here report how aberrantly expressed A3B induces DNA mutations and 
deletions and affects the survival of MM patients.
Results
A3B expression is aberrantly high in most malignant plasma cell samples from MM/MGUS 
patients and is associated with poor prognosis. First, we investigated the expression levels and gen-
otypes of A3B in samples from MM/MGUS patients in our institutes. The patient characteristics are shown 
in Supplemental Table 1. MGUS patients accounted for 22.0% (n = 20), newly diagnosed multiple myeloma 
(NDMM) patients accounted for 45.1% (n = 41) and relapse/refractory MM (RRMM) patients accounted for 33% 
(n = 30) of a total of 91 patients. For 39 patients, we obtained the RNA of CD138+ myeloma cells from bone mar-
row samples to examine A3B expression. Because it was very difficult to obtain sufficient CD138-sorted plasma 
cells, PBMCs from healthy individuals were used as negative controls. Quantitative PCR analysis showed remark-
ably high expression levels of A3B in the majority of MM/MGUS patients (range, 0 to 1.214; median, 0.991; 
control vs MM/MGUS, P = 0.00397; control vs MM, P = 0.001; Fig. 1a, left panel). Regarding A3B genotypes, 
a deletion polymorphism that removes the entire A3B gene has been reported, and its frequency varies among 
major continental regions25,26. We examined the frequency of the A3B deletion allele in our patients and found 
that 44 were wild type (I/I, 48.4%; 95% CI, 37.7–59.1%), 40 were heterozygous (D/I, 44.0%; 95% CI, 33.6–54.8%), 
and 7 were homozygous for the deletion allele (D/D, 7.7%; 95% CI, 3.1–15.2%). There was no significant differ-
ence in allele frequency between MM/MGUS patients and Japanese healthy controls26 (Supplemental Table 2), 
although the A3B deletion allele tended to be more prevalent in MGUS (15.0%; 95% CI, 3.2–37.9%) than in MM 
(5.6%; 95% CI, 1.6–13.8%) patients (Supplemental Table 2). A3B expression levels were significantly correlated 
with A3B genotype (P = 0.0189; Fig. 1a, middle panel) and showed a weak positive correlation with diagnosis 
(MGUS vs MM, P = 0.0543; Fig. 1a, left panel) but were not correlated with disease status (NDMM vs RRMM, 
P = 0.642; Fig. 1a, right panel).
Next, to investigate the clinical impact of each APOBEC, we analysed a microarray dataset of 414 NDMM 
patients from Arkansas University7. Among the APOBEC genes whose probes were available in the platform 
of the study, A3B expression reached very high levels (Supplemental Fig. 1a), although A3B is generally not 
expressed in normal tissues27. It has been recently described that patients with an absolute APOBEC signature 
contribution at diagnosis in the fourth quartile have worse progression-free survival and overall survival (OS) 
than patients in the first to third quartiles17. Thus, we divided the cohort into two groups: a high-APOBEC 
group including patients whose expression of each APOBEC as determined by microarray data was over the 
fourth quartile limit and a low-APOBEC group including patients with APOBEC expression under that limit. 
Importantly, only A3B was correlated with a significantly worse OS (A3B high group: 3-year OS, 66.2%; 95% 
confidence interval [CI], 52.9–76.5% vs A3B low group: 3-year OS, 81.8%; 95% CI, 75.6–86.5%; P = 0.00133; 
Supplemental Fig. 1b). Because A3B expression is correlated with known risk factors16, we also assessed OS after 
risk group stratification based on genetic signatures7 to exclude potential confounding biases. Consistent with a 
previous report16, A3B expression differed significantly between the molecular subgroups (Supplemental Fig. 1c, 
P = 1.17 × 10−14). Univariate analysis showed that A3B expression levels still had a significant prognostic impact 
in the high-risk group (Supplemental Fig. 1d, right panel, P = 0.00357) as well as over long-term observation 
periods in the low-risk group (Supplemental Fig. 1d, left panel; P = 0.143, logrank test and P = 0.00357, 45-month 
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landmark analysis). Univariate analysis also detected high A3C, high A3DE and low A3F as significant risk factors 
when the median was used as the threshold (Supplemental Table 3). However, only known risk and high A3B 
remained independent risk factors for OS after multivariate analysis following a Cox regression model (known 
high-risk group: hazard ratio [HR], 2.342; 95% CI, 1.503–3.649; P = 0.0001693 and high A3B: HR, 2.057; 95% CI, 
1.294–3.270; P = 0.0002305; Supplemental Table 3).
A3B is highly upregulated and localized at the nucleoplasm in MM cell lines. We next investigated 
the expression profiles of AID and APOBEC3 family members in seven myeloma cell lines: OPM2, MMK1, U266, 
Figure 1. APOBEC family gene expression levels in MM/MGUS patients and myeloma cell lines. (a) Real-
time PCR analysis of CD138-positive cells from MM/MGUS patient bone marrow. Statistical analysis of the 
correlation between A3B mRNA levels and diagnosis (healthy vs MGUS vs MM), genotype (D/D vs D/I vs I/I), or 
disease status (newly diagnosed MM [NDMM] vs relapse/refractory MM [RRMM]). The relative quantity of A3B 
mRNA was normalized by HPRT1 mRNA. P values were calculated using the Mann-Whitney U test (*), Kruskal-
Wallis test (†) or Jonckheere-Terpstra test (§). (b) Real-time PCR of each of the APOBEC3 family genes (from 
A3A to A3H) and AID in seven myeloma cell lines (OPM2, MMK1, U266, RPMI8226, THK72, SKMM1 and 
AMO1). The target mRNA expression levels were normalized by HPRT1 mRNA levels. The target mRNA levels 
from PBMCs were used as a reference. (c) Immunoblot analysis of A3B in SUDHL6 cells (negative controls), 
KIS1 cells (positive controls) and the seven myeloma cell lines. α-Tubulin was evaluated as an internal control. 
(d) Fluorescence immunostaining using an anti-A3B antibody in SUDHL6, RPMI8226, THK72, SKMM1 and 
AMO1 cells. The images were obtained by confocal fluorescence microscopy (magnification, 630x).
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Figure 2. APOBEC3B mediates the loss of function of exogenous genes in myeloma cells. (a) Schema of the 
shRNA lentiviral vector construct. The produced lentivirus transduces shRNA together with mCherry and the 
puromycin resistance gene (puroR). (b,c) Real-time PCR (b) and immunoblotting (c) results of A3B levels in 
RPMI8226 cells, which were transduced with lentiviral shRNA against A3B (two constructs: shA3B and shA3B-
2) or control shRNA (two constructs: control and control-2). HPRT1 or α-tubulin was evaluated as an internal 
control. (d) Immunofluorescence analysis using an anti-A3B antibody of RPMI8226 cells transduced with 
either shRNA against A3B or control lentivirus. The images were obtained by confocal fluorescence microscopy 
(magnification, 630x). (e) In vitro assay for cytidine deaminase activity in RPMI8226 cells transduced with either 
shRNA against A3B or control lentivirus. The asterisks indicates the cleaved DNA products. (f) Flow cytometry 
of RPMI8226 cells at 3 and 31 days after transduction with each mCherry-shRNA lentivirus. The numbers in 
boxes indicate the proportions of mCherry-positive cells among the live cells for each condition. (g) Time-
dependent changes in the proportions of mCherry-positive cells among live cells transduced with each shRNA 
lentivirus as determined by flow cytometry. (h) Representative figure of the EF1α promoter methylation assay. 
The black circles represent methylated CpG. The shaded box indicates the deleted region. The sense strands of 
the EF1α promoter and a portion of the mCherry gene region are shown for reference. The pink boxes indicate 
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THK72, RPMI8226, SKMM1 and AMO1. Consistent with the results from primary myeloma cells, these cell lines 
also expressed prominently high levels of A3B, as determined by quantitative PCR analysis (quantity relative to 
that in PBMCs: range, 1.22 to 489.4; median, 62.47; Fig. 1b). Cap analysis of gene expression (CAGE) in these 
seven myeloma cell lines showed that the activity of both A3B promoters was aberrantly upregulated compared to 
that in CD19+ cells from healthy individuals (Supplemental Fig. 2). We next determined protein expression levels 
using an anti-A3B antibody that we generated by immunizing rabbits with a C-terminal A3B peptide28. Because 
of the high homology of the C-termini, this anti-A3B antibody also detects artificially overexpressed A3A and 
A3G (Supplemental Fig. 3a,b). However, at endogenous expression levels, the antibody is more specific for A3B 
than for A3G (Supplemental Fig. 3c). We could also distinguish among these three proteins based on their sizes in 
immunoblot analyses (A3A, 25 kDa; A3B, 35 kDa; A3G, 40 kDa) and by their subcellular localization in immuno-
fluorescence assays (A3A, cytoplasm and nucleus; A3B, nucleus; A3G, cytoplasm) (Supplemental Fig. 3a–c). We 
demonstrated that there was aberrant expression of A3B at the protein level in each MM cell line by immunob-
lotting (Fig. 1c) and confirmed A3B expression in the nuclei, but not in the nucleoli or in the cytoplasm, by using 
immunofluorescence assays (Fig. 1d); these findings were consistent with previous evidence23.
Endogenous A3B overexpression contributes to loss of function of lentivirally introduced 
genomic DNA and to constitutive DNA double-strand breaks in myeloma cells. To assess the 
mutagenic activity of endogenous A3B in MM cells, we transduced RPMI8226 cells with lentiviral shRNA against 
A3B (shA3B) and with an EF1α-driven mCherry fluorescent marker (Fig. 2a). We confirmed A3B depletion 
at the mRNA and protein levels (Fig. 2b–d) and confirmed that there was little cytidine deaminase activity in 
shA3B-transduced cells (Fig. 2e). Notably, lentiviral shA3B transduction also efficiently decreased endogenous 
A3B expression in other MM cell lines, such as THK72, SKMM1 and AMO1, which are susceptible to lentivirus 
infection (Supplemental Fig. 3d,e). Interestingly, control shRNA-transduced cells lost mCherry fluorescence over 
a span of three weeks, whereas shA3B-transduced cells stably maintained it in the RPMI8226 cell line (Fig. 2f,g) 
as well as the THK72 and AMO1 cell lines (Supplemental Fig. 4a–d). To investigate this fluorescence loss, we 
determined the DNA methylation status of the EF1α promoter by bisulfite sequencing. DNA methylation was 
absent in both control shRNA- and shA3B-transduced cells, indicating that DNA methylation-mediated silencing 
did not cause the loss of fluorescence. Instead, we detected a large deletion accompanied by 6 bp microhomology 
(i.e., CGCCGT) at the junction point in the EF1α promoter in control shRNA-transduced cells (Fig. 2h). Using 
real-time PCR to quantify the copy number of the transduced mCherry genes, we detected a faster decrease in con-
trol shRNA-transduced cells than in shA3B-transduced cells (Fig. 2i). In addition, amplification of the full-length 
shRNA construct failed at day 21 in control shRNA-transduced cells (Fig. 2j). These data support the premise that 
the loss of fluorescence was caused by deletion mutations and/or ablation of the intact transduced gene.
Myeloma cells have been reported to exhibit constitutive DNA double-strand breaks (DSBs)29; therefore, we 
next investigated whether A3B knockdown changes the status of γ-H2AX, a DSB marker. shA3B transduction sig-
nificantly reduced γ-H2AX protein levels, which was confirmed by fluorescence immunostaining in RPMI8226 
and AMO1 cells (Fig. 3a,b) and immunoblot analysis in RPMI8226 cells (Fig. 3c,d). These results suggest that 
A3B contributes to constitutive DSBs leading to gene alterations in myeloma cells.
A3B constantly generates C>t|G>A transitions, which are then processed by the DNA repair system. 
We further tested the mutagenic activity of A3B by differential DNA denaturation PCR (3D-PCR), which effi-
ciently amplifies DNA containing C>T|G>A transitions30. The mCherry sequences were amplified at lower dena-
turation temperatures in control shRNA-transduced than in shA3B-transduced RPMI8226 and AMO1 cells, both 
at Day 3 and at Day 21 after transduction (Fig. 4a). 3D-PCR of the puromycin resistance gene (puroR) also pro-
duced similar results (Fig. 4b). Using TA cloning and Sanger sequencing, we confirmed prominent G-to-A muta-
tions in the mCherry gene (Fig. 4c and Supplemental Table 4) that are typical of the APOBEC signature (Fig. 4d). 
Intriguingly, we detected only G-to-A mutations, indicating that C-to-U deamination preferentially occurs in the 
antisense strand of the gene (Fig. 4c and Supplemental Table 4). Deep sequencing of the 3D-PCR products of the 
mCherry-T2A-puroR gene demonstrated that only G-to-A transitions accumulated throughout the gene and that 
the frequency of mutations increased towards the 3′ region of the gene (Fig. 4e and Supplemental Fig. 5a). Of note, 
Sanger sequencing of the 3D-PCR products showed that the occurrence of the C>T|G>A transition was similar 
between Day 3 and Day 21 (Fig. 4c). In contrast, deep sequencing of conventional PCR products of the mCherry 
gene failed to detect substitutions (Supplemental Fig. 5b). These findings demonstrate that mutations amplified 
by 3D-PCR occur in the presence (and occur less in the absence) of A3B in at least some fraction of cells or that 
DNA repair pathways might repair A3B-mediated DNA lesions. In fact, the 3D-PCR products of both control 
and shA3B-transduced cells contained large deletions that had at least 3-base microhomology at the junction 
points, suggesting that these mutations are at least in partly repaired by the microhomology-mediated end-joining 
(MMEJ) machinery31 (Fig. 4f and Supplemental Table 4). The results of bisulfite sequencing of the EF1α promoter 
after conventional PCR also supported the involvement of MMEJ repair (Fig. 2h). Additionally, the combination of 
substitutions and deletions varied among the clones obtained from control cells, resulting in different amino acid 
sequences (Fig. 4f, Supplemental Tables 4 and 5). Abolition of the mCherry chromophore was predicted in clones 
microhomology at the DNA double-strand breakpoint. (i) Real-time PCR of genomic mCherry. RPMI8226 
genomic DNA expression at 3 and 15 days after transduction with each shRNA lentivirus was examined. APOB 
was evaluated as an internal control. The value at day 3 was used as a reference. (j) Conventional PCR of the 
full-length viral vector DNA. RPMI8226 genomic DNA expression at 3 and 21 days after transduction with each 
shRNA lentivirus was examined. The arrow indicates the amplicon size between the two LTR regions of the 
lentiviral vector (5200 bp).
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that contained approximately hundreds of base deletions, suggesting that loss of mCherry fluorescence was at least 
partly caused by these deletion mutations (Supplemental Table 5).
We confirmed gene amplification at lower denaturation temperatures by 3D-PCR after shA3B transduction 
in two other A3B-expressing myeloma cell lines, including AMO1 (Fig. 4a, lower panel). Importantly, aurintri-
carboxylic acid and myricetin, which are known APOBEC3 deaminase inhibitors32, also allowed for 3D-PCR 
amplification of the mCherry gene at lower denaturation temperatures in myeloma cells (Fig. 4g), suggesting that 
this cell-based model could be used for screening APOBEC3B inhibitors.
Figure 3. APOBEC3B promotes DNA double-strand breaks in myeloma cells. (a) Fluorescence 
immunostaining of γ-H2AX in RPMI8226 and AMO1 cells transduced with either control or A3B shRNA 
lentivirus. The images were obtained by confocal fluorescence microscopy (magnification, 630x). (b) Statistical 
analysis of the number of γ-H2AX foci per cell in RPMI8226 and AMO1 cells based on the images in (a). 
Approximately 200 cells were evaluated for each sample. All P values were calculated using Student’s t test. (c) 
Immunoblot analysis of γ-H2AX in RPMI8226 cells transduced with either control or A3B shRNA lentivirus. 
(d) Bar graph of the γ-H2AX band intensities from (c) normalized by the α-tubulin band intensity.
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Figure 4. APOBEC3B induces C>T|G>A mutations in lentivirally introduced genomic DNA in myeloma 
cells. (a,b) 3D-PCR analysis of mCherry genes (a) and puromycin resistance genes (puroR) (b) derived from 
RPMI8226 genomic DNA at 3 or 21 days post transduction with each shRNA lentivirus. 3D-PCR analysis of 
mCherry genes derived from AMO1 genomic DNA at 3 days post transduction with each shRNA lentivirus 
is also indicated in (a). (c) Mutation matrices of hyperedited mCherry sequences derived from RPMI8226 
genomic DNA at 3 (upper panel) and 21 (lower panel) days post transduction with each shRNA lentivirus. The 
sequence data were obtained by performing TA cloning and Sanger sequencing. The first column indicates 
the bases before mutation, and the first line indicates the bases after mutation. The highlighted boxes indicate 
significant C-to-T or G-to-A substitutions. The sense strand of the mCherry sequence was used as a reference. 
(d) Sequence logo created with WebLogo indicating the frequencies of nucleotides adjacent to C-to-T mutation 
sites. (e) Deep sequencing analysis of the 3D-PCR products of mCherry-T2A-puroR genes derived from 
RPMI8226 genomic DNA at 21 days post transduction with each shRNA lentivirus. The Y axis indicates the 
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Lastly, we examined the state of several endogenous genes that are known to be frequently mutated (e.g., TP53 
and KRAS) or in which breakpoints are observed in translocations frequently occurring in myeloma cells (e.g., in 
the MYC intergenic region)8 (Fig. 5a). APOBEC signature mutations are known to be associated with DNA break-
points20. Promoter regions of BCL6 and BCL7A were also selected because cooperation between A3B and tran-
scription factors has been reported33. Intriguingly, we detected significant 3D-PCR amplification of genes such as 
TP53 and the BCL6 and BCL7A promoters but little difference in KRAS (Fig. 5b). These data are consistent with 
previous reports showing that TP53-inactivating mutations are commonly found throughout the TP53 gene and 
that KRAS-activating mutations are limited to hot spots (G12/G13/Q61/A146)34. We did not detect significant 
amplification in MYC intergenic regions, possibly because the MYC breakpoint is found in the megabase-wide 
intergenic region of MYC35, while our primer sets for MYC 3D-PCR analysis only covered 700 and 679 base pairs 
(Fig. 5a). Sanger sequencing of the mutated TP53 genes confirmed C>T|G>A transitions (Fig. 5c,d) and dele-
tions (Fig. 5e), as summarized in Fig. 5f. We confirmed that these G>A|C>T transitions in TP53 in the 3D-PCR 
product were reproducible in other cell lines, such as AMO1 and THK72 (Supplemental Fig. 6a–f). These results 
indicate that A3B mutates endogenous genes in genomic DNA as well as exogenous genes in transduced DNA, 
in our case the mCherry-T2A-puroR gene. These data suggest that most DNA substitutions induced by overex-
pressed A3B will be repaired by DNA repair pathways and that some clones will survive in the long term under 
selective pressure in myeloma cells.
Discussion
The present study demonstrates that endogenous A3B overexpression constitutively produces various combina-
tions of C>T|G>A mutations and promotes DSB-related gene alterations in myeloma cells. Recent studies have 
demonstrated that there are clinical consequences of APOBEC activity in malignant tumours36, especially in 
breast cancer19,21. Previous genome-wide analyses of MM/MGUS samples have also shown that mutation patterns 
associated with APOBEC activity correlate with disease progression and clinical outcomes11,16,17, whereas those 
associated with AID activity contribute to disease initiation37. In ER-positive breast cancer, high A3B expression 
has been reported to correlate with treatment resistance, metastasis and poor prognosis22,38, and there have been 
similar reports for lung cancer39 and ovarian cancer40. Our analyses also show that aberrant A3B expression could 
have an impact on prognosis in MM patients, as A3B may contribute to disease progression and drug resistance. 
The present study is the first to specifically investigate the activity of endogenous A3B and to demonstrate its 
on-going mutagenic effects in myeloma cells. Importantly, A3B knockdown profoundly decreased the cytidine 
deaminase activity of whole-cell lysates from myeloma cells, suggesting that among APOBECs, A3B plays a major 
role in cytidine deamination-related mutagenesis in myeloma cells (Fig. 2e). On the other hand, breast cancer 
also shows APOBEC signature mutations in the absence of A3B, intimating the involvement of other APOBEC 
proteins, such as A3A41 and A3H haplotype I42. A recent study showed that A3H haplotype I is associated with 
APOBEC signature mutations in lung and breast cancer42. We also found A3H to be relatively highly expressed in 
MM cell lines (Fig. 1b and Supplemental Fig. 2), suggesting the possible involvement of A3H-induced mutations 
in MM. Further studies are needed to confirm whether the A3H haplotype contributes to MM oncogenesis.
The precise mechanism of APOBEC-induced mutagenesis of genomic DNA is under intense investigation. 
Because APOBECs preferentially target single-stranded DNA (ssDNA), three situations have been proposed: first, 
that APOBECs target the lagging DNA strand under replication stress43–45; second, that they target ssDNA during 
the resection phase of homology-mediated repair after DSBs20,36,43; and third, that they target the non-transcribed 
strand during transcription46–48. Interestingly, in the present study, endogenous A3B deaminated cytosines mainly 
in the antisense strand (Fig. 4c,e and Supplementary Fig. 5a), suggesting that, instead, the transcribed strand 
might be the major A3B target. This discrepancy could have arisen due to differences in methodology; for exam-
ple, 3D-PCR selectively amplifies minor clones of mutated DNA, whereas next-generation sequencing detects 
DNA mutations established through selection pressure or the DNA repair response.
Our data also suggested that lentivirally transduced genes lose their function due to deletions of hundreds 
of bases with microhomology at the junction points in A3B-overexpressing myeloma cells. It is plausible that 
multiplex attacks by A3B on ssDNA could cause DSBs, and subsequent MMEJ repair would produce a variety 
of clones harbouring deletions of various lengths. Whole-genome/exome sequencing with a coverage of tens to 
hundreds is usually able to detect only clones that account for more than a single-digit percentage of the total. 
Therefore, A3B-associated minor clones would be buried in sequencing errors and neglected. Since MMEJ repair 
of DSBs is undertaken at microhomology sequences near the breakpoint, clones with different DSB locations 
could be transformed into clones with the same deleted region. In fact, in our study, a number of clones with 
different combinations of mutations also had the same deleted region, as was revealed by TA cloning and Sanger 
sequencing (Figs 2h, 4f). However, most of the major mapping programs used for next generation sequencing, 
e.g., BWA and BWA-MEM49,50, do not cover deletions of hundreds of bases such as the large deletions in mCherry 
proportion of each substitution in the total coverage, and the X axis indicates its location in the amplified gene 
from the EF1α promoter to the puroR gene. (f) Schema of Sanger sequencing results of each of the 10 clones 
of mCherry 3D-PCR products at 3 days post transduction with each shRNA lentivirus. G-to-A substitutions 
are indicated in green, C-to-T substitutions in red, G-to-C substitutions in light blue, and A-to-T substitutions 
in orange. The black squares indicate single-base deletions, whereas the dotted lines represent large deletions. 
The pink, purple or yellow boxes indicate microhomology at the DNA double-strand breakpoint. (g) 3D-PCR 
of EGFP derived from RPMI8226 genomic DNA at 10 days post transduction with control shRNA lentivirus 
under continuous incubation with the APOBEC3 inhibitors myricetin (5 μM) and aurintricarboxylic acid (ATA, 
1 μM). We used lentiviral shRNA against APOBEC3B as a positive control.
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Figure 5. APOBEC3B exerts its mutagenic activity on endogenous genes. (a) Primer settings for 3D-PCR 
of the endogenous genes of interest. The white boxes indicate 5′- or 3′-UTR sequences, and the black boxes 
indicate protein-coding sequences. The white and grey triangles represent the first and second PCR primer 
sets, respectively. (b) 3D-PCR of particular loci in genomic DNA obtained from RPMI8226 cells at 21 days post 
transduction with control or shA3B lentivirus. The loci include TP53 from exon 1 (Ex1) to intron 1 (Int1) and 
from exon 7 (Ex7) to intron 8 (Int8), the BCL6 promoter, the BCL7A promoter, KRAS from intron 1 (Int1) to 
intron 2 (Int2), and the MYC intergenic region (IGR). (c) Mutation matrices of hyperedited TP53 sequences from 
Ex1 to Int1 obtained from RPMI8226 genomic DNA at 21 days post transduction with each shRNA lentivirus. 
The sequence data were obtained by performing TA cloning and Sanger sequencing. The first column indicates 
the bases before mutation, and the first line indicates the bases after mutation. The sense strand of TP53 was 
used as a reference. C-to-T and G-to-A substitutions are highlighted. (d) Sequence logo created with WebLogo 
indicating the frequencies of nucleotides adjacent to C-to-T mutation sites in TP53 Ex1-Int1. (e) Representative 
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(195 bp at minimum) detected in our study. Paired-end read analysis can detect structural variance, including 
large deletions of thousands of bases; nevertheless, sequenced reads that contain approximately hundreds of base 
deletions are unlikely to be mapped and will generally be discarded. Methods to obtain comprehensive snapshots 
of the production of minor clones in vivo still need to be validated.
Regarding mutation of endogenous genes, we observed enrichment of C-to-T substitutions and deletions in 
intronic regions and non-coding exons in the endogenous TP53 gene, consistent with previous reports8. Chapman 
et al. demonstrated that the mutation frequency in coding regions was lower than that observed in UTR/pro-
moter, intronic and intergenic regions in MM samples8. DNA repair responses, including transcription-coupled 
repair, might preferentially correct mutations in coding regions51, or one or more unknown mechanisms might 
preferentially protect these regions from A3B attacks. Indeed, analysis of large whole-genome and exome datasets 
from bladder, cervical, breast, lung and head and neck cancers has indicated only a weak positive correlation 
between A3B expression and APOBEC-induced mutagenesis36. APOBEC-mediated mutations may develop as a 
result of the interplay between deaminase activity and the DNA damage response52. A limitation to using 3D-PCR 
for endogenous genes is the considerable PCR error rate. Suspene et al. stated that the 3D-PCR error rate is 0.02% 
owing to constant selection for AT DNA and PCR-mediated recombination53. In our study, the transition rate 
was 0.029% in the shA3B-derived genome, whereas in the control cells, the rate was elevenfold higher (0.345%, 
Fig. 5c). Accordingly, sequencing of the 3D-PCR products detected only background mutations in shA3B sam-
ples, but significantly more mutations were detected in control samples. Still, the mutational signature present 
in TP53 appeared to be a complex cytosine mutation distribution rather than the typical A3B pattern (Fig. 5d). 
Previous studies on overexpressed A3B also showed similar results24,54, and the authors discussed the possibility 
that the intrinsic preference of A3B was skewed by downstream repair pathways or other mutation-generating 
processes54. Our data showing that mutational signatures were different between exogenous and endogenous 
genes despite the use of the same DNA inputs may support their hypothesis. Regarding the substitution rate, 
C>T|G>A transitions were much more frequent in the exogenous genes (2.728% in mCherry-T2A-puroR, 
Fig. 4c) than in the endogenous genes (0.345% in TP53, Fig. 5c) of control samples. One of the reasons behind 
these different rates might be that lentivirally transduced genes are processed by the DNA repair system differ-
ently than endogenous genomic genes. Further studies are needed to clarify this issue.
In conclusion, aberrantly highly expressed endogenous A3B can contribute to genomic instability and there-
fore to linear and branched clonal evolution in the context of long-term disease progression. Although the clinical 
impact of A3B-related oncogenesis in myeloma remains to be further evaluated, inhibiting A3B activity could 
protect against disease deterioration and could be a new therapeutic option.
Materials and Methods
Clinical samples. All investigations have been conducted in accordance with ethical standards and have 
been approved by the Institutional Review Boards of Kyoto University and Nagoya City University, respectively. 
Written informed consent for the banking and subsequent research using their specimens, including genomic 
studies, was obtained from each patient. Bone marrow mononuclear cells were first obtained after centrifugation 
of bone marrow aspirates using the Lympholyte®-H (CEDARLANE) density gradient separation medium, and 
then myeloma cells were further isolated using the MACS CD138 positive cell isolation kit (Miltenyi Biotec). To 
assess the A3B polymorphism, the intact (I) and deletion (D) alleles were genotyped as previously described55.
Cell lines and cell culture. Six human myeloma cell lines, OPM2, U266, RPMI8226, THK7256, SKMM1 
and AMO1, and two B-cell lymphoma cell lines, SUDHL6 and KIS128, were maintained in RPMI1640 (Nacalai) 
containing 10% FBS and 1% PSG (Invitrogen). The MMK1 myeloma cell line was established in our laboratory by 
culturing primary myeloma cells from the pleural effusion of a refractory myeloma male patient.
Quantitative Rt-pCR. Total RNA was extracted from clinical samples and cell lines using the High Pure 
RNA isolation kit (Roche). Complementary DNA was synthesized using the PrimeScriptR II 1st strand cDNA 
Synthesis Kit (Takara) by random primer and oligo dT primer mixture. Real-time PCR was performed using the 
Thunderbird SYBR qPCR Mix (ToYoBo). Target gene expression levels were normalized by endogenous expres-
sion levels of HPRT1. To assess the copy number of introduced mCherry genes in lentivirally transduced cells, 
genomic DNA was extracted using the QuickGene DNA whole blood kit S (KURABO) and was evaluated and 
normalized by the endogenous APOB allele. All primers for real-time PCR are listed in Supplemental Table 6.
CAGe analysis. Promoter-level gene expression analysis was performed using CAGE57. Total RNA from 
each cell line was isolated using the RNeasy Mini Kit (Qiagen) and assessed with the Agilent RNA6000 Nano 
Kit (Agilent Technologies). 5 µg of total RNA (RIN > 7, A260/280 and 260/230 ratios > 1.7) was used for CAGE 
library preparation. CAGE libraries were made based on no-amplification non-tagging CAGE libraries for 
Illumina next-generation sequencers (nAnT-iCAGE) as previously described57. After Illumina sequencing, we 
used the MOIRAI pipeline58 to remove ribosomal RNA (rRNA) sequences and sequences with base ‘N’, and to 
align the reads. In the pipeline, rRNAdust (http://fantom.gsc.riken.jp/5/suppl/rRNAdust/) was used to remove 
rRNA with rRNA sequences (U13369.1) and the parameters of −e 2 and −t 8. Mapping to the hg19 reference 
genome was done using bwa -aln (version 0.5.9)49 with the parameters of −n 0.02, −o 1, −e −1, −i 5, −d 10, −l 
colony PCR results for TP53 from Ex1 to Int1 (left) and from Ex7 to Int8 (right) after TA cloning. Clones 
derived from control- or shA3B- transduced cells were selected from the PCR products obtained at the lowest 
denaturation temperatures in (b). The arrows indicate the intact sizes of the nested PCR products for TP53 
(700 bp and 639 bp). (f) Summary of Sanger sequencing for the 3D-PCR products of TP53 Ex1-Int1 and Ex7-Int8.
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32, −k 2, −m 2000000, −t 8, −M 3, −O 11, −E 4, −R 30, −q 0. Using samtools version 0.1.859, the resultant SAM 
files were converted to BAM files and low-quality nucleotides (MAPQ < 10) were filtered out. 5′ ends of reads 
were counted on FANTOM5-defined CAGE peaks60 based on the annotation file retrieved on April 25th, 2017 
from the link below. Tags per million (TPM) normalized expression values were used. (http://fantom.gsc.riken.
jp/5/datafiles/latest/extra/CAGE_peaks/hg19.cage_peak_phase1and2combined_ann.txt.gz.)
Immunoblot analysis. Whole cell lysates were subjected to immunoblot analysis using a purified rab-
bit anti-A3B polyclonal antibody, a mouse anti-phospho-histone H2A.X (Ser139) antibody (Millipore, clone 
JBW301) or a mouse anti-α-tubulin monoclonal antibody (AA13, Funakoshi). The anti-A3B antibody was gen-
erated from a rabbit immunized with the C-terminal peptide EEHSQALSGRLRAILQNQGN by Sigma Aldrich 
as previously described28.
Knockdown experiments. We constructed pSicoR-mCherry/EGFP lentiviral vectors61 express-
ing short-hairpin RNA (shRNA) against A3B by inserting synthetic double-stranded oligonucleotides 
(TRCN000014054619, sense oligo, 5′-TGCAAAGCAATGTGCTCCTGATCTCGAGATCAGGAGCACATTGCTT 
TGCTTTTTTC-3′, and antisense oligo, 5′-TCGAGAAAAAAGCAAAGCAATGTGCTCCTGATCTCGAGATCA 
GGAGCACATTGCTTTGCA-3′; TRCN0000139463, sense oligo, 5′-TCCTGATGGATCCAGACACATTCT 
CGAGAATGTGTCTGGATCCATCAGGTTTTTTC-3′, and antisense oligo, 5′-TCGAGAAAAAACCTGA 
TGGATCCAGACACATTCTCGAGAATGTGTCTGGATCCATCAGGA-3′) into the cloning site. For non-target 
shRNA, we used two constructs that were cloned as scrambled sequences (control62, sense oligo, 5′-TGTCAAGTC 
TCACTTGCGTCTTCAAGAGAGACGCAAGTGAGACTTGACTTTTTTC-3′, antisense oligo, 5′-TCGAGAA 
AAAAGTCAAGTCTCACTTGCGTCTCTCTTGAAGACGCAAGTGAGACTTGACA-3′; control-263, sense 
oligo, 5′-TATCTCGCTTGGGCGAGAGTAAGCTCGAGCTTACTCTCGCCCAAGCGAGATTTTTTTC-3′, 
antisense oligo, 5′-TCGAGAAAAAAATCTCGCTTGGGCGAGAGTAAGCTCGAGCTTACTCTCGCCCAA 
GCGAGATA). The lentivirus was produced by co-transfection of Trans-Lentiviral packaging plasmid mix (GE 
Dharmacon) and pSicoR-mCherry/EGFP into Lenti-X cells. Physical particle titers were measured using the 
RETRO-TEK HIV-1 p24 Antigen ELISA kit (ZeptoMetrix) and matched titers of each lentiviral vector (control 
vs shA3B) were used.
A3B catalytic domain biochemistry. The DNA deamination assay was performed as previously 
described64. Cell lysates were mixed with a 6-FAM labeled 43-long oligonucleotide containing a TTCC deamina-
tion site for 30 min at 37 °C before adding uracil DNA glycosylase and NaOH to create and break an abasic site. 
The samples were separated on 15% acrylamide-urea gels and analyzed with the Gel Doc EZ system.
3D-PCR and Deep sequencing. For DNA editing assays, genomic DNA was extracted as described above 
from myeloma cells at 3 and 21 days after transduction by pSicoR-mCherry shRNA lentivirus. We performed 
3D-PCR30 by amplifying genes using the KOD FX Neo (ToYoBo) DNA polymerase as described before24. All 
primer sets and conditions are listed in Supplemental Table 6. For Sanger sequencing, amplicons derived at the 
lowest temperature were incubated with A-attachment Mix (ToYoBo) and were subsequently cloned into the 
T-vector pMD20 (TaKaRa). Each extracted plasmid from DH5α cells (ToYoBo) transformed with the cloned vec-
tor was sequenced using the 3130xl Genetic Analyzer (Applied Biosystems). For deep sequencing analysis, ampli-
cons (5 ng) derived at the lowest temperature were sheared and sequenced on an Illumina NextSeq instrument to 
obtain 75 nucleotides paired end reads. After Illumina sequencing, low-quality nucleotides (MAPQ < 10) were 
discarded and then Illumina sequencing adapters and primers sequences were removed from the reads. Finally, 
the reads were aligned using the BWA-MEM algorithm with default settings (version 0.7.12)50.
Immunofluorescence assays. Myeloma cells were air-dried and fixed in 4% paraformaldehyde in 
phosphate-buffered saline (PBS) for 20 minutes on glass slides using Shandon cytospin 2 (THERMO FISHER 
SCIENTIFIC). Fixed cells were permeabilized, reduced and denatured for 30 minutes in PBS buffer containing 
0.5% SDS, 5% β-mercaptoethanol and 10% FBS. Then, cells were washed three times with PBS containing 4% 
FBS and 0.1% Triton X-100 (PFT buffer)65, and incubated with a purified rabbit anti-A3B antibody for 1 hour. 
Subsequently, cells were incubated with a goat anti-rabbit IgG (H + L)-Alexa Fluor® 488 preadsorbed antibody 
(Abcam, ab150081) for 30 min in the dark. γ-H2AX foci analysis was performed as previously described29 using a 
mouse anti-phospho-histone H2A.X (Ser139) antibody (Millipore, clone JBW301) as primary antibody and a goat 
anti-mouse IgG (H + L)-Alexa Flour® 594 preadsorbed antibody (Abcam, ab150120) as secondary antibody. All 
antibodies were diluted with 3% BSA and 0.5% Tween in PBS. Around two hundred cells were observed and scored 
with a confocal laser scanning microscope (TCS-SP8, Leica) or a fluorescence microscope (BZ-9000, KEYENCE).
Bisulfite sequencing analysis. To examine CpG methylation levels in the EF1α promoter region transduced 
by the pSicoR lentiviral vector, 500 ng of extracted genomic DNA was converted using the MethylEasy Xceed kit 
(Human Genetic Signatures). First-round PCR was performed by Quick Taq HS DyeMix (ToYoBo) using 25 ng 
of converted DNA in a 10 µl reaction mixture, then 0.5 µl of the first-round PCR product was used as template for 
nested PCR in a 25 μl reaction mixture. All primer sets and conditions are listed in Supplemental Table 6.
Datasets. To examine the association between A3B expression and clinical outcomes, we used the Arkansas 
dataset (GSE4581)7, which consists of MAS5 normalized gene expression profiles generated using the Affymetrix 
U133Plus2.0 microarray platform and clinical information from the Multiple Myeloma Genomics Portal 
(MMGP) (http://portals.broadinstitute.org/mmgp/home).
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statistical analysis. Descriptive statistics included absolute and relative frequencies for categorical data 
and median, mean, and range for numerical measurements. Mann-Whitney U test, Kruskal-Wallis test or 
Jonckheere-Terpstra trend test were used to evaluate the differences in continuous variables between two groups 
or more than three groups. Probabilities of OS were calculated based on Kaplan-Meier product limit estimates, 
and the OS outcomes of the two groups divided according to APOBECs expression levels were compared using 
the Logrank test. P values less than 0.05 were considered statistically significant. Multivariate analysis was per-
formed using a Cox proportional hazard model for OS. Covariates with a P value < 0.2 factor in the univariate 
analysis were entered into the model. All statistical analyses were performed with EZR (Saitama Medical Center, 
Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, 
version 3.0.2)66.
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